PCVX
Vaxcyte Inc. Healthcare - Biotechnology Investor Relations →
Vaxcyte Inc. (PCVX) closed at $56.15 as of 2026-02-02, trading 5.4% above its 200-week moving average of $53.27. The stock moved further from the line this week, up from 0.9% last week. The 14-week RSI sits at 67, indicating neutral momentum.
Over the past 247 weeks of data, PCVX has crossed below its 200-week moving average 2 times. On average, these episodes lasted 59 weeks. Historically, investors who bought PCVX at the start of these episodes saw an average one-year return of +34.1%.
With a market cap of $8.1 billion, PCVX is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -20.8%. The stock trades at 2.5x book value.
Share count has increased 135.5% over three years, indicating dilution.
Over the past 4.8 years, a hypothetical investment of $100 in PCVX would have grown to $256, compared to $176 for the S&P 500. That represents an annualized return of 21.5% vs 12.3% for the index — confirming PCVX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: PCVX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After PCVX Crosses Below the Line?
Each line shows $100 invested at the moment PCVX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
PCVX has crossed below its 200-week MA 2 times with an average 1-year return of +34.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2021 | Oct 2022 | 75 | 38.1% | +34.1% | +187.2% |
| Mar 2025 | Jan 2026 | 43 | 40.9% | N/A | +77.7% |
| Average | 59 | — | +34.1% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02